13 completed, 6 active not recruiting, 4 recruiting, 4 terminated. 16 Phase 2, 13 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Indolent Non-hodgkin Lymphoma: new trials by email Literature Review of Indolent Non-hodgkin Lymphoma trials Research Report on Indolent Non-hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Bendamustine, Rituximab - Lymphoma, Indolent Non-hodgkin Lymphoma | Phase 2 | Not yet recruiting | Fox Chase Cancer Center | 24 | 2025-06-01 | 2025-01-06 |
| Studying TAK-243 in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 95 | 2025-03-24 | 2026-10-13 |
| Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma Obinutuzumab, Glofitamab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Active not recruiting | Reid Merryman, MD | 47 | 2023-07-18 | 2026-09-25 |
| The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients Biospecimen Collection, Cardiopulmonary Exercise Testing, Dual X-ray Absorptiometry - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent Non-hodgkin Lymphoma | Not applicable | Recruiting | Mayo Clinic | 70 | 2023-06-12 | 2026-04-09 |
| A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies CNTY-101, IL-2, Lymphodepleting Chemotherapy - R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma | Phase 1 | Terminated | Century Therapeutics, Inc. | 28 | 2023-01-24 | 2025-12-18 |
| A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Antengene Corporation | 54 | 2022-04-07 | 2025-06-09 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. CAR.k.28, Fludarabine, Cyclophosphamide - Mantle Cell Lymphoma, Follicular Lymphoma | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 20 | 2020-11-12 | 2026-01-20 |
| 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers 19(T2)28z1xx CAR T cells - Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma | Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2020-07-06 | 2026-08-27 |
| Testing the Safety of CB-5339 in Patients With Cancer p97 Inhibitor CB-5339 Tosylate - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2020-06-18 | 2025-09-17 | |
| Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib - Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma | Phase 1 | Active not recruiting | Mayo Clinic | 50 | 2020-06-15 | 2026-02-02 |
| IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma IBI376 - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 81 | 2020-04-07 | 2024-06-05 |
| NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255, NKTR-255 Q21, Rituximab - Multiple Myeloma, Non-Hodgkin Lymphoma | Phase 1 | Completed | Nektar Therapeutics | 30 | 2019-10-07 | 2023-06-15 |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma Duvelisib - Indolent Non-Hodgkin Lymphoma | Phase 2 | Completed | SecuraBio | 103 | 2019-09-24 | 2024-09-19 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma Copanlisib, Nivolumab - Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 27 | 2019-07-10 | 2026-08-21 |
| Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma | Phase 2 | Active not recruiting | David Bond, MD | 30 | 2019-01-02 | 2026-02-06 |
| Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas Ibrutinib, Obinutuzumab, Laboratory Biomarker Analysis - Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2018-02-20 | 2026-08-18 |
| First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years Obinutuzumab, Bendamustine - Indolent Non-hodgkin Lymphoma | Phase 2 | Completed | Prof. Dr. Wolfgang Hiddemann | 46 | 2017-12-12 | 2023-03-31 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma Axicabtagene ciloleucel, Cyclophosphamide, Fludarabine - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Completed | Kite, A Gilead Company | 159 | 2017-06-06 | 2025-12-23 |
Showing 20 of 30. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Follicular (11) · Lymphoma, Large B-Cell, Diffuse (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Mantle-Cell (8) · Multiple Myeloma (5) · Hodgkin Disease (4) · Lymphoma, Non-Hodgkin (4) · Leukemia, Myeloid, Acute (3) · Lymphoma (3) · Myelodysplastic Syndromes (3) · Myeloproliferative Disorders (3) · Waldenstrom Macroglobulinemia (3) · Burkitt Lymphoma (2) · Hematologic Neoplasms (2)
Neoplasms (25) · Hemic and Lymphatic Diseases (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Lymphatic Diseases (24) · Neoplasms by Histologic Type (24) · Lymphoproliferative Disorders (23) · Lymphoma (20) · Lymphoma, B-Cell (17) · Lymphoma, Non-Hodgkin (17) · Pathologic Processes (14) · Pathological Conditions, Signs and Symptoms (14) · Disease Attributes (12) · Hematologic Diseases (12) · Chronic Disease (11)
Cyclophosphamide (6) · Rituximab (5) · fludarabine phosphate (5) · obinutuzumab (5) · Mycophenolic Acid (4) · Peripheral Blood Stem Cell Transplantation (4) · Whole-Body Irradiation (4) · Bendamustine Hydrochloride (3) · Cyclosporine (3) · Cyclosporins (3) · fludarabine (3) · CT-P10 (2) · Doxorubicin (2) · Etoposide (2) · Nivolumab (2)
Fred Hutchinson Cancer Center (4) · Mayo Clinic (3) · National Cancer Institute (NCI) (2) · SecuraBio (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Antengene Corporation (1) · Century Therapeutics, Inc. (1) · City of Hope Medical Center (1) · David Bond, MD (1) · Emory University (1) · Fox Chase Cancer Center (1) · Gilead Sciences (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Kite, A Gilead Company (1) · Ludwig-Maximilians - University of Munich (1)
United States (23) · Germany (5) · France (3) · Italy (3) · China (2) · Czechia (2) · United Kingdom (2) · Belarus (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Georgia (1) · Hungary (1) · Japan (1)
Brenda Sandmaier (2) · Ajay Gopal (1) · Alexey V Danilov (1) · David A Bond, MD (1) · Jae Park, MD (1) · Jonathon B Cohen, MD, MS (1) · Marcus Messmer (1) · Michael P. Gustafson, PhD (1) · Naoko Takebe (1) · Natalie Grover, MD (1) · Rachel Salit (1) · Reid Merryman, MD (1)
PMID 32499241, PMID 30742566, PMID 31248843, PMID 32856068, PMID 34001523, PMID 34154392, PMID 34515338, PMID 39240498, PMID 39883889, PMID 40536814, PMID 40550489, PMID 41100801, PMID 42745632
P30CA015704 (4), 2014 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), P01CA018029 (1), P01CA044991 (1), P01CA078902 (1), P30CA033572 (1), P30CA138292 (1), P50CA097274 (1), R01CA193140 (1), R01CA219960 (1)